National Asbestos Awareness Week an Opportunity for Weitz & Luxenberg to Shine Spotlight on Dangers of Asbestos, Causes for Hope

Share Article

Weitz & Luxenberg, PC, today announced an initiative to advance the state of cancer research by promoting awareness about asbestos. The initiative comes during a week specifically set aside to promote public knowledge about the only known cause of mesothelioma, one of the deadliest forms of cancer.

Asbestos is directly linked with a disease that is a terrible killer. Normally a disease like that would be a priority, but since there is no awareness about asbestos, there is no outcry against it.

Weitz & Luxenberg today announced its ongoing commitment to an initiative intended to promote asbestos awareness and increase the availability of funds earmarked for cancer research. The announcement comes during National Asbestos Awareness Week.

Weitz & Luxenberg, a leading national mass-tort and personal-injury litigation law firm, said it is taking this week to reinforce the importance of spreading the message about the continued prevalence of asbestos, and highlighting how public ignorance about asbestos prevents asbestos cancers from getting adequate research funding.

Pleural mesothelioma – an aggressive cancer that affects the lining of the lungs – is uniquely situated in a public blind spot and qualifies as an “orphan disease,” meaning that it receives essentially no public funding due to its relative rarity, the firm said in a prepared statement.

“While diseases like breast cancer receive hundreds of millions of dollars per year in research funds, according to the National Cancer Institute, mesothelioma researchers generally have to squeak by on privately-raised donations supplemented by minimal governmental support,” Weitz & Luxenberg said. “The result is that the quantity of high-profile mesothelioma research studies is limited.”

There are, however, some groundbreaking projects being undertaken by researchers: Weitz & Luxenberg offered the example of a medicine being developed by Italian biotech company MolMed that targets for destruction tumor blood vessels (MolMed announced in October that the drug being tested, NGR-hTNF, was set to undergo clinical testing).

“Nevertheless, the lack of public support for researching mesothelioma and banning asbestos can hamstring cancer researchers trying to find a cure,” the firm said. “One of the big problems with mesothelioma is the lack of awareness about it. Asbestos is directly linked with a disease that is a terrible killer. Normally a disease like that would be a priority, but since there is no awareness about asbestos, there is no outcry against it. And since there is no outcry, there is less funding. Funding for research like the MolMed study and other therapies is crucial, and the first step is making the problem known.”

To that end, Weitz & Luxenberg said it sponsored a February charity race that advanced both goals – asbestos awareness and research funding. Larry Davis, a mesothelioma survivor and the race’s organizer, has worked with partners like Weitz & Luxenberg to raise over $100,000 for non-chemotherapy mesothelioma research, the firm reported.

*****************************

About Weitz & Luxenberg

Founded in 1986 by attorneys Perry Weitz and Arthur Luxenberg, Weitz & Luxenberg, P.C., today ranks among the nation’s leading law firms. Weitz & Luxenberg’s numerous litigation areas include: mesothelioma, defective medicine and devices, environmental pollutants, accidents, personal injury, and medical malpractice. Victims of accidents are invited to rely on Weitz & Luxenberg’s more than 20 years of handling such cases – begin by contacting the firm’s Client Relations department at 1-800-476-6070 or at clientrelations@weitzlux.com and ask for a free legal consultation. More information: http://www.weitzlux.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dave Kufeld
Weitz & Luxenberg P.C.
1-800-476-6070
Email >
Visit website